Bromo-DragonFLY
| Bromo-DragonFLY | |
|---|---|
| Chemical name | Bromo-benzodifuranyl-isopropylamine or (1-(8-bromobenzo[1,2-b;4,5-b']difuran-4-yl)-2-aminopropane |
| Chemical formula | C13H12BrNO2 |
| Molecular mass | 294.15 g/mol |
| Melting point | decomposes at 240 °C (hydrochloride) |
| CAS number | - |
| SMILES | N[C@H](C)CC1=C(OC=C2)C2=C(Br)C3=C1C=CO3 (R-isomer) |
| Missing image R-Bromo-DragonFLY.png chemical structure of (R)-Bromo-DragonFLY | |
Bromo-DragonFLY is a psychedelic hallucinogenic drug of the phenethylamine family. Bromo-DragonFLY is considered an extremely potent hallucinogen, comparable in dosage to LSD, and it has an extremely long duration of action. Bromo-DragonFLY has a stereocenter and R-(-)-bromo-DragonFLY is the more active stereoisomer.
| Contents |
Pharmacology
The hallucinogenic effect of bromo-DragonFLY is mediated by its partial agonistic activity at the 5-HT2A serotonin receptor, but bromo-DragonFLY also has a high binding affinity for the 5-HT2B and 5-HT2C serotonin receptor.
History
Bromo-DragonFLY was first synthesized by Matthew A. Parker in the laboratory of David E. Nichols in 1998.
See also
External links
References
- 'A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor' by M. A. Parker, D. Marona-Lewicka, V. L. Lucaites, D. L. Nelson, and D. E. Nichols in J. Med. Chem. 41(26): 5148-5149 (1998) DOI: 10.1021/jm9803525
- 'Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT2A/2C receptor agonists' by J. J. Chambers, D. M. Kurrasch-Orbaugh, M. A. Parker, and D. E. Nichols in J. Med. Chem. 44(6): 1003-1010 (2001) DOI: 10.1021/jm000491y
Categorization
| Psychedelic phenethylamines edit |
|---|
|
{2C-B} {2C-C} {2C-D} {2C-E} {2C-I} {2C-N} {2C-P} {2C-T-2} {2C-T-21} {2C-T-4} {2C-T-7} {2C-T-8} {3C-E} {Br-DFLY} {DOB} {DOI} {DOM} {Escaline} {MDA} {MBDB} {MDEA} {Mescaline} {TMA} |
